原发性肝癌合并门静脉癌栓的研究进展
Recent Advances on Primary Liver Cancer with Portal Vein Tumor Thrombus
DOI: 10.12677/acm.2025.1551446, PDF,   
作者: 陈辉帆, 梁舒惟, 韦慧怡, 李 宇, 韩 澳, 张沚汀：广西中医药大学研究生院，广西 南宁；俞 渊, 庞浇安：广西中医药大学第一附属医院肝胆外科，广西 南宁；黎舒琴：钦州市第一人民医院产科，广西 钦州
关键词: 原发性肝癌；门静脉癌栓；研究进展；治疗；Primary Hepatocellular Carcinoma； Portal Vein Thrombosis； Research Progress； Treatment
摘要: 门静脉癌栓(portal vein tumor thrombosis, PVTT)，是原发性肝癌(primary liver cancer, PLC)发展至中晚期的一个重要临床表现，不仅对肝细胞的临床治疗构成挑战，也是影响预后的关键因素。近年来，随着对PVTT发病机制的深入了解，及免疫治疗药物、肝动脉灌注化疗(hepatic arterial infusion chemotherapy, HAIC)、载药微球TACE (TACE with drug-eluting beads, DEB-TACE)等新型治疗方式的出现，给肝细胞癌合并门静脉癌栓的诊断方式和治疗策略带来了新的理解。这些治疗手段的更新显著提高了治疗效果，并改善了预后情况。
Abstract: Portal vein tumor thrombosis (PVTT), an important clinical manifestation of primary liver cancer (PLC) in the middle and late stages of development, not only poses a challenge to the clinical treatment of hepatocellular carcinoma, but also is a key factor affecting the prognosis. In recent years, with the in-depth understanding of the pathogenesis of PVTT and the emergence of new therapeutic modalities such as immunotherapeutic drugs, hepatic arterial infusion chemotherapy (HAIC) and TACE with drug-eluting beads (DEB-TACE), have reshaped diagnostic approaches and therapeutic strategies for HCC complicated by PVTT. These newer therapeutic modalities have significantly improved the therapeutic efficacy and prognosis.
文章引用：陈辉帆, 俞渊, 庞浇安, 梁舒惟, 韦慧怡, 李宇, 韩澳, 张沚汀, 黎舒琴. 原发性肝癌合并门静脉癌栓的研究进展[J]. 临床医学进展, 2025, 15(5): 882-890. https://doi.org/10.12677/acm.2025.1551446

参考文献

[1] Zhang, X., Gao, Y., Chen, Z., Chen, M., Li, L., Wen, T., et al. (2019) An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology, 69, 2076-2090. [Google Scholar] [CrossRef] [PubMed]
[2] Katagiri, S. and Yamamoto, M. (2013) Multidisciplinary Treatments for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus. Surgery Today, 44, 219-226. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, F., Lu, C., Zhang, X., Chen, Z., Zhong, C., Hu, Y., et al. (2020) The Impact of Portal Vein Tumor Thrombus on Long-Term Survival after Liver Resection for Primary Hepatic Malignancy. HPB, 22, 1025-1033. [Google Scholar] [CrossRef] [PubMed]
[4] 滕金豪, 俞渊, 刘春丽, 等. MDT模式下中国原发性肝癌的外科治疗现状[J]. 安徽医学, 2023, 44(6): 736-740.
[5] 方强, 汪华霖, 龚建平. 肝癌合并门静脉癌栓的研究进展[J]. 中国现代普通外科进展, 2014, 17(10): 838-840.
[6] 周俭, 樊嘉, 肖永胜. 肝细胞癌门静脉癌栓形成机制[J]. 实用肿瘤杂志, 2009, 24(5): 425-428.
[7] 程倩, 李照, 朱继业. 门静脉癌栓形成机制的研究进展[J]. 中 华实验外科杂志, 2018, 35(12): 2373-2377.
[8] Lin, T., Lin, Z., Mai, P., Zhang, E. and Peng, L. (2021) Identification of Prognostic Biomarkers Associated with the Occurrence of Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Aging, 13, 11786-11807. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, D., Zhu, Y., Tang, J., Lian, Q., Luo, G., Wen, W., et al. (2019) Integrative Molecular Analysis of Metastatic Hepatocellular Carcinoma. BMC Medical Genomics, 12, Article No. 164. [Google Scholar] [CrossRef] [PubMed]
[10] 程树群, 李楠, 吴孟超. 门静脉癌栓分型与治疗选择[J]. 中国普外基础与临床杂志, 2012, 19(3): 240-242.
[11] 肝细胞癌合并血管侵犯专家共识(讨论稿) [J]. 肝癌电子杂志, 2015, 2(3): 1-11.
[12] 刘文静, 迟男男. 腹部超声对原发性肝癌患者门静脉高压及门静脉癌栓的诊断价值[J]. 川北医学院学报, 2024, 39(8): 1068-1071.
[13] 周伟, 蒋雪峰, 朱玉春, 等. 肝脏门静脉血栓与癌栓的发病机制及影像学表现[J]. 基层医学论坛, 2018, 22(1): 120-122.
[14] 韩凯, 王广志. 肝细胞癌合并门静脉癌栓的MRI增强、DWI及ADC表现及临床价值[J]. 医学影像学杂志, 2024, 34(10): 75-78.
[15] Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., et al. (2016) Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Hepatology, 65, 938-943. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, J., Lao, Y., Yuan, B., Yin, J., Liu, X., Chen, L., et al. (2017) Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Advances and Challenges. Oncotarget, 8, 33911-33921. [Google Scholar] [CrossRef] [PubMed]
[17] 中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
[18] Zhang, Y., Wu, J. and Li, L. (2022) Efficacy Comparison of Optimal Treatments for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. Annals of Hepatology, 27, Article ID: 100552. [Google Scholar] [CrossRef] [PubMed]
[19] Yu, J., Zhuang, L., Liu, P., Liu, Z., Ling, S., Deng, Y., et al. (2022) Long-Term Outcomes of Deceased Donor Liver Transplantation in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Multicenter Study. European Journal of Surgical Oncology, 48, 121-132. [Google Scholar] [CrossRef] [PubMed]
[20] 王纪玲. 肝移植与肝切除对符合米兰标准的HCC患者预后的Meta分析[D]: [硕士学位论文]. 长春: 吉林大学, 2023.
[21] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版) [J]. 中华消化外科杂志, 2022, 21(4): 433-443.
[22] Herrero, A., Toubert, C., Bedoya, J.U., Assenat, E., Guiu, B., Panaro, F., et al. (2024) Management of Hepatocellular Carcinoma Recurrence after Liver Surgery and Thermal Ablations: State of the Art and Future Perspectives. Hepatobiliary Surgery and Nutrition, 13, 71-88. [Google Scholar] [CrossRef] [PubMed]
[23] Du, Z., Wei, Y., Chen, K. and Li, B. (2014) Risk Factors Associated with Early and Late Recurrence after Curative Resection of Hepatocellular Carcinoma: A Single Institution’s Experience with 398 Consecutive Patients. Hepatobiliary & Pancreatic Diseases International, 13, 153-161. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, Z., Zhang, X., Zhou, T., Wang, K., Wang, H., Chai, Z., et al. (2019) Adjuvant Transarterial Chemoembolization Improves Survival Outcomes in Hepatocellular Carcinoma with Microvascular Invasion: A Systematic Review and Meta-Analysis. European Journal of Surgical Oncology, 45, 2188-2196. [Google Scholar] [CrossRef] [PubMed]
[25] Deng, J., Liao, Z. and Gao, J. (2023) Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-analysis. Current Oncology, 30, 1243-1254. [Google Scholar] [CrossRef] [PubMed]
[26] Xia, W., Zhao, X., Guo, Y., Hu, H., Cao, G., Li, Z., et al. (2023) Transarterial Chemoembolization Combined with Apatinib plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clinical and Translational Gastroenterology, 14, e00581. [Google Scholar] [CrossRef] [PubMed]
[27] Zhou, G., Han, J., Sun, J., Zhang, Y., Zhou, T., Nie, C., et al. (2018) Efficacy and Safety Profile of Drug-Eluting Beads Transarterial Chemoembolization by Callispheres® Beads in Chinese Hepatocellular Carcinoma Patients. BMC Cancer, 18, Article No. 644. [Google Scholar] [CrossRef] [PubMed]
[28] 李一帆, 李臻, 余鹏, 等. 不同粒径载药微球序贯TACE用于治疗巨块型原发性肝癌伴肝静脉或门静脉癌栓[J]. 中国介入影像与治疗学, 2024, 21(5): 307-309.
[29] Zhou, T., Tao, G., Zhou, G., Zhang, Y., Zhu, T., Chen, S., et al. (2024) Comparison of Drug-Eluting Bead with Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized Clinical Trial. International Journal of Surgery, 110, 5527-5537. [Google Scholar] [CrossRef] [PubMed]
[30] 赵荣策, 韦玮, 李少华, 等. 肝动脉灌注化疗在肝癌围手术期的应用及研究进展[J]. 中国肿瘤外科杂志, 2022, 14(2): 105-110.
[31] Si, T., Huang, Z., Khorsandi, S.E., Ma, Y. and Heaton, N. (2022) Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Frontiers in Bioengineering and Biotechnology, 10, Article ID: 1010824. [Google Scholar] [CrossRef] [PubMed]
[32] 袁叶菊, 徐成臣, 陶新光, 等. 经导管肝动脉栓塞术联合I125粒子导管植入治疗原发性肝癌合并门静脉癌栓的疗效分析[J]. 齐齐哈尔医学院学报, 2024, 45(18): 1718-1722.
[33] Huang, J., Cai, M., Huang, W., Guo, Y., Zhou, J., Liang, L., et al. (2021) Transarterial Chemoembolization Combined with Sorafenib and Iodine-125 Seed Brachytherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Controlled Study. Chinese Medical Journal, 135, 113-115. [Google Scholar] [CrossRef] [PubMed]
[34] 贾中芝, 朱春富, 徐后云, 等. 钇-90微球放射栓塞治疗肝细胞性肝癌伴门静脉癌栓的安全性与疗效评价[J]. 中华普通外科杂志, 2019, 34(5): 439-443.
[35] Martelletti, C., Ricotti, A., Gesualdo, M., Carucci, P., Gaia, S., Rolle, E., et al. (2021) Radioembolization vs Sorafenib in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score and Bayesian Analysis. Journal of Digestive Diseases, 22, 496-502. [Google Scholar] [CrossRef] [PubMed]
[36] Wei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., et al. (2019) Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 37, 2141-2151. [Google Scholar] [CrossRef] [PubMed]
[37] 景静源. TACE联合3DCRT治疗原发性肝癌合并门静脉癌栓的近远期疗效及对其生存的影响[J]. 医学理论与实践, 2021, 34(13): 2255-2257.
[38] Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359, 378-390. [Google Scholar] [CrossRef] [PubMed]
[39] 谢宝杰, 朱丽娜, 张凤娟, 等. 索拉非尼治疗原发性肝癌合并PVTT患者的临床治疗效果研究[J]. 基因组学与应用生物学, 2018, 37(6): 2685-2689.
[40] 赵莹, 黎可人, 杨艳美, 等. 放射治疗联合免疫检查点抑制剂及仑伐替尼治疗肝细胞癌合并门静脉癌栓的疗效分析[J]. 肝癌电子杂志, 2023, 10(3): 58-63.
[41] Cheng, A., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T., et al. (2022) Updated Efficacy and Safety Data from Imbrave150: Atezolizumab plus Bevacizumab Vs. Sorafenib for Unresectable Hepatocellular Carcinoma. Journal of Hepatology, 76, 862-873. [Google Scholar] [CrossRef] [PubMed]
[42] Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., et al. (2021) Donafenib versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. Journal of Clinical Oncology, 39, 3002-3011. [Google Scholar] [CrossRef] [PubMed]
[43] Li, H., Wang, J., Zhang, G., Kuang, D., Li, Y., He, X., et al. (2023) Transarterial Chemoembolization Combined Donafenib with/without PD-1 for Unresectable HCC in a Multicenter Retrospective Study. Frontiers in Immunology, 14, Article ID: 1277329. [Google Scholar] [CrossRef] [PubMed]
[44] Yau, T., Kang, Y., Kim, T., El-Khoueiry, A.B., Santoro, A., Sangro, B., et al. (2020) Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncology, 6, e204564. [Google Scholar] [CrossRef] [PubMed]
[45] Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study. The Lancet Oncology, 22, 977-990. [Google Scholar] [CrossRef] [PubMed]
[46] Kudo, M., Yau, T., Decaens, T., Sangro, B., Qin, S., Da Fonseca, L., et al. (2025) Nivolumab (NIVO) Plus Ipilimumab (IPI) vs Lenvatinib (LEN) or Sorafenib (SOR) as First-Line (1L) Therapy for Unresectable Hepatocellular Carcinoma (uHCC): CheckMate 9DW Expanded Analyses. Journal of Clinical Oncology, 43, 520-520. [Google Scholar] [CrossRef] 
[47] Chen, Z., Lin, Z., Chen, Y., Chen, J. and Chen, J. (2018) Clinical Efficacy of Endovascular Radiofrequency Ablation in the Treatment of Portal Vein Tumor Thrombus of Primary Hepatocellular Carcinoma. Journal of Cancer Research and Therapeutics, 14, 145-149. [Google Scholar] [CrossRef] [PubMed]
[48] Zhou, Q., An, Y., Liu, T., Liu, Z., Li, R., Wang, C., et al. (2022) Prognosis of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus Treated with Combination of Transarterial Chemoembolization and Palliative Thermal Ablation. International Journal of Hyperthermia, 39, 97-107. [Google Scholar] [CrossRef] [PubMed]

为你推荐